12 studies found for:    Open Studies | "Carcinoma, Islet Cell"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Carcinoma, Islet Cell"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Endometrial Papillary Serous Carcinoma;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Gastrointestinal Carcinoid Tumor;   Ovarian Carcinosarcoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Papillary Serous Carcinoma;   Pancreatic Alpha Cell Adenoma;   Pancreatic Alpha Cell Carcinoma;   Pancreatic Beta Islet Cell Adenoma;   Pancreatic Beta Islet Cell Carcinoma;   Pancreatic Delta Cell Adenoma;   Pancreatic Delta Cell Carcinoma;   Pancreatic G-cell Adenoma;   Pancreatic G-cell Carcinoma;   Pancreatic Polypeptide Tumor;   Pulmonary Carcinoid Tumor;   Recurrent Adult Primary Liver Cancer;   Recurrent Endometrial Carcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Regional Gastrointestinal Carcinoid Tumor;   Stage IIIA Endometrial Carcinoma;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Endometrial Carcinoma;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Endometrial Carcinoma;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer;   Stage IVA Endometrial Carcinoma;   Stage IVB Endometrial Carcinoma;   Uterine Carcinosarcoma
Interventions: Drug: temsirolimus;   Biological: bevacizumab
2 Recruiting Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Islet Cell Carcinoma;   Pancreatic Polypeptide Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma
Interventions: Drug: temozolomide;   Drug: capecitabine;   Other: laboratory biomarker analysis
3 Recruiting Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery
Conditions: Pancreatic Alpha Cell Carcinoma;   Pancreatic Beta Islet Cell Carcinoma;   Pancreatic Delta Cell Carcinoma;   Pancreatic G-cell Carcinoma;   Recurrent Islet Cell Carcinoma
Interventions: Drug: temozolomide;   Drug: pazopanib hydrochloride
4 Not yet recruiting Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed By Surgery
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Pancreatic Polypeptide Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma
Interventions: Biological: ziv-aflibercept;   Radiation: computed tomography perfusion imaging;   Other: laboratory biomarker analysis
5 Not yet recruiting Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Liver Metastases;   Pancreatic Polypeptide Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma
Interventions: Drug: everolimus;   Other: placebo;   Other: laboratory biomarker analysis
6 Recruiting Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Pancreatic Polypeptide Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Pancreatic Cancer;   Somatostatinoma;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: capecitabine;   Drug: temozolomide;   Biological: bevacizumab
7 Not yet recruiting Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Pancreatic Polypeptide Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma
Interventions: Drug: dovitinib lactate;   Other: pharmacological study;   Other: laboratory biomarker analysis
8 Recruiting Gallium Ga 68-Edotreotide PET/CT Compared With Indium In 111 Pentetreotide Plus Contrast-Enhanced CT (or MRI) in Diagnosing Patients With Neuroendocrine Tumors and Other Somatostatin Receptor Positive Tumors
Conditions: Adult Medulloblastoma;   Childhood Medulloblastoma;   Neuroblastoma;   Neuroendocrine Tumor;   Somatostatinoma
Interventions: Radiation: gallium Ga 68-edotreotide;   Procedure: positron emission tomography/computed tomography;   Radiation: indium In 111 pentetreotide;   Procedure: computed tomography;   Procedure: contrast-enhanced magnetic resonance imaging
9 Recruiting YF476 in Patients With Type II Gastric Carcinoids Associated With Zollinger-Ellison Syndrome
Condition: Carcinoid
Intervention: Drug: YF476
10 Recruiting Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
Conditions: Islet Cell Tumor;   Pancreatic Cancer;   Pancreatic Disease
Interventions: Other: medical chart review;   Other: survey administration;   Other: biospecimen collection
11 Recruiting Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Metastatic Cancer
Intervention: Drug: PVA microporous hydrospheres/doxorubicin hydrochloride
12 Unknown  Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
Conditions: Brain and Central Nervous System Tumors;   Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Neuroblastoma;   Pheochromocytoma;   Sarcoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Radiation: yttrium Y 90-edotreotide

Indicates status has not been verified in more than two years